Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma
Copyright © 2023 Elsevier Inc. All rights reserved..
PURPOSE: The use of systemic immune checkpoint blockade before surgery is increasing in patients with metastatic renal cell carcinoma, however, the safety and feasibility of performing consolidative cytoreductive nephrectomy after the administration of systemic therapy are not well described.
PATIENTS AND METHODS: A retrospective review of patients undergoing nephrectomy was performed using our prospectively maintained institutional database. Patients who received preoperative systemic immunotherapy were identified, and the risk of postoperative complications were compared to those who underwent surgery without upfront systemic treatment. Perioperative characteristics and surgical complications within 90 days following surgery were recorded.
RESULTS: Overall, we identified 220 patients who underwent cytoreductive nephrectomy from April 2015 to December 2022, of which 46 patients (21%) received systemic therapy before undergoing surgery. Unadjusted rates of surgical complications included 20% (n = 35) in patients who did not receive upfront systemic therapy and 20% (n = 9) in those who received upfront systemic immunotherapy. In our propensity score analysis, there was no statistically significant association between receipt of upfront immunotherapy and 90-day surgical complications [odds ratio (OR): 1.82, 95% confidence interval (CI): 0.59-5.14; P = 0.3]. This model, however, demonstrated an association between receipt of upfront immunotherapy and an increased odds of requiring a blood transfusion [OR: 4.53, 95% CI: 1.83-11.7; P = 0.001].
CONCLUSION: In our cohort, there was no significant difference in surgical complications among patients who received systemic therapy before surgery compared to those who did not receive upfront systemic therapy. Cytoreductive nephrectomy is safe and with low rates of complications following the use of systemic therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Urologic oncology - 42(2024), 2 vom: 15. Feb., Seite 32.e9-32.e16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reese, Stephen W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytoreductive nephrectomy |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urolonc.2023.12.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366262866 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366262866 | ||
| 003 | DE-627 | ||
| 005 | 20240411232213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2023.12.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM366262866 | ||
| 035 | |a (NLM)38135627 | ||
| 035 | |a (PII)S1078-1439(23)00470-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reese, Stephen W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: The use of systemic immune checkpoint blockade before surgery is increasing in patients with metastatic renal cell carcinoma, however, the safety and feasibility of performing consolidative cytoreductive nephrectomy after the administration of systemic therapy are not well described | ||
| 520 | |a PATIENTS AND METHODS: A retrospective review of patients undergoing nephrectomy was performed using our prospectively maintained institutional database. Patients who received preoperative systemic immunotherapy were identified, and the risk of postoperative complications were compared to those who underwent surgery without upfront systemic treatment. Perioperative characteristics and surgical complications within 90 days following surgery were recorded | ||
| 520 | |a RESULTS: Overall, we identified 220 patients who underwent cytoreductive nephrectomy from April 2015 to December 2022, of which 46 patients (21%) received systemic therapy before undergoing surgery. Unadjusted rates of surgical complications included 20% (n = 35) in patients who did not receive upfront systemic therapy and 20% (n = 9) in those who received upfront systemic immunotherapy. In our propensity score analysis, there was no statistically significant association between receipt of upfront immunotherapy and 90-day surgical complications [odds ratio (OR): 1.82, 95% confidence interval (CI): 0.59-5.14; P = 0.3]. This model, however, demonstrated an association between receipt of upfront immunotherapy and an increased odds of requiring a blood transfusion [OR: 4.53, 95% CI: 1.83-11.7; P = 0.001] | ||
| 520 | |a CONCLUSION: In our cohort, there was no significant difference in surgical complications among patients who received systemic therapy before surgery compared to those who did not receive upfront systemic therapy. Cytoreductive nephrectomy is safe and with low rates of complications following the use of systemic therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytoreductive nephrectomy | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Kidney cancer | |
| 650 | 4 | |a Metastatic renal cell carcinoma | |
| 650 | 4 | |a Nephrectomy | |
| 700 | 1 | |a Eismann, Lennert |e verfasserin |4 aut | |
| 700 | 1 | |a White, Charlie |e verfasserin |4 aut | |
| 700 | 1 | |a Villada, Juan Arroyave |e verfasserin |4 aut | |
| 700 | 1 | |a Khaleel, Sari |e verfasserin |4 aut | |
| 700 | 1 | |a Ostrovnaya, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Vazquez-Rivera, Katiana |e verfasserin |4 aut | |
| 700 | 1 | |a Carlo, Maria I |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Darren |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chung-Han |e verfasserin |4 aut | |
| 700 | 1 | |a Motzer, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Voss, Martin H |e verfasserin |4 aut | |
| 700 | 1 | |a Kotecha, Ritesh R |e verfasserin |4 aut | |
| 700 | 1 | |a Matulewicz, Richard S |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Alvin |e verfasserin |4 aut | |
| 700 | 1 | |a Coleman, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hakimi, A Ari |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologic oncology |d 1995 |g 42(2024), 2 vom: 15. Feb., Seite 32.e9-32.e16 |w (DE-627)NLM097435058 |x 1873-2496 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:32.e9-32.e16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urolonc.2023.12.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 2 |b 15 |c 02 |h 32.e9-32.e16 | ||